CRCT · 152 people with mild-moderate AD, 90 days

Study of the ketogenic agent AC-1202 in mild to moderate Alzheimer's disease: a randomized, double-blind, placebo-controlled, multicenter trial

ST Henderson, JL Vogel, LJ Barr et al.. Nutrition & Metabolism. 2009.

Published 2026-10-15Sources checked 2026-10-151 sourceEverstack research teamHow we work

In plain language: A caprylic MCT product improved ADAS-Cog at day 45, with lasting benefit mainly in APOE4 non-carriers.
Limits: Industry-run; benefit faded by day 90 in the full group.
Source: doi.org/10.1186/1743-7075-6-31 · PubMed 19664276

Summary written by Everstack from the published abstract. Verified against Crossref on 2026-10-15. The authors do not endorse Everstack.